PLAINSBORO, N.J. & BAGSVAERD, Denmark, April 29, 2026
Novo Nordisk has announced that its investigational therapy denecimig (Mim8) significantly reduced the annualized bleeding rate (ABR) in adults and adolescents with hemophilia A, regardless of inhibitor status, according to new Phase 3 FRONTIER2 trial data published in the New England Journal of Medicine (NEJM). The study demonstrated that both once-monthly and once-weekly dosing of denecimig provided major bleeding reduction compared to prior clotting factor prophylaxis and on-demand treatment, strengthening its potential as a next-generation preventive therapy for this rare and serious bleeding disorder
Significant Reduction in Bleeding Episodes Across All Patient Groups
The pivotal FRONTIER2 Phase 3 trial evaluated 254 adults and adolescents aged 12 years and older with hemophilia A, with or without Factor VIII inhibitors. Patients receiving denecimig once-monthly experienced nearly 99% fewer treated bleeds compared to on-demand treatment and approximately 43% fewer bleeds compared to previous clotting factor prophylaxis. Similarly, once-weekly dosing showed around 96% fewer treated bleeds versus on-demand treatment and 54% fewer bleeds compared to prior preventive therapy
In the denecimig treatment arms, 64% to 95% of participants reported zero treated bleeds, compared with only 0% to 37% in comparator groups. These results demonstrate strong efficacy across different dosing schedules and reinforce the therapy’s potential to reduce both disease burden and long-term treatment complexity.
Innovative FVIIIa Mimetic Designed for Lower Treatment Burden
Advertisement
Denecimig (Mim8) is an investigational bispecific antibody Factor VIIIa mimetic designed for routine prophylaxis in hemophilia A patients with or without inhibitors. Administered subcutaneously, denecimig works by mimicking the function of Factor VIIIa, bridging Factor IXa and Factor X to restore thrombin generation and support healthy blood clot formation
Unlike traditional frequent clotting factor replacement therapies, denecimig is being developed for flexible once-monthly, once-every-two-weeks, or once-weekly dosing, significantly reducing treatment burden. This could provide a major quality-of-life improvement for patients managing lifelong bleeding risk and frequent injections.
The study also showed a strong safety profile, with denecimig generally well tolerated. No thromboembolic events or neutralizing anti-drug antibodies were reported, while injection-site reactions occurred in only 10% of participants and were seen in just 2.6% of injections
Regulatory Progress and Future Commercial Potential
Novo Nordisk submitted a Biologics License Application (BLA) for denecimig to the U.S. FDA in September 2025, and the newly published NEJM data further strengthen its regulatory case. The company continues to advance the broader FRONTIER clinical program, which includes studies across pediatric and adult populations with different dosing strategies and inhibitor profiles.
Hemophilia A accounts for approximately 80–85% of all hemophilia cases worldwide, with an estimated 836,000 people affected globally, and nearly 30% of patients develop inhibitors, making treatment more complex
With strong Phase 3 efficacy, convenient dosing flexibility, and positive regulatory momentum, denecimig is emerging as a potentially transformative prophylactic therapy for hemophilia A, reinforcing Novo Nordisk’s leadership in rare blood disorder innovation.
Source: Novo Nordisk press release
